Zhixiang Jintai (688443.SH) signed an authorization and commercialization agreement with Cullinan for the GR1803 injection solution.

Zhixun Finance and Economics APP news, Zhixiang Jintai (688443.SH) announced on June 4, 2025, that the company signed an exclusive licensing and cooperation agreement with Cullinan Therapeutics, Inc. (NASDAQ stock code: CGEM; hereinafter referred to as "Cullinan") for GR1803 injection. The GR1803 is a bispecific antibody that can simultaneously bind to the BCMA and CD3 antigens, thereby directing cytotoxic T cells to cells expressing BCMA. According to the agreement, Cullinan will have the development, production, and commercialization rights for GR1803 injection outside the Greater China region (including Hong Kong, Macao, and Taiwan), while Zhixiang Jintai will retain all indication rights in the Greater China region. In addition, Zhixiang Jintai will explore research related to autoimmune diseases in the mainland China region for the GR1803 injection project, initiate clinical trials as required, and authorize clinical data for Cullinan's use in exchange for compensation.